Steatosis News and Research

RSS

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.

1 Nov 2012

Dietary habits associated with NAFLD in obese children

Research has identified a number of variables associated with nonalcoholic fatty liver disease in obese children.

27 Sep 2012

High uric acid precursor of obesity, metabolic syndrome

The relationship between uric acid and early cardiometabolic risk may precede obesity and the metabolic syndrome, show study findings.

20 Sep 2012

Usefulness of liver biopsy for CALI preoperative assessment questioned

Liver biopsy is not a reliable tool for preoperative assessment of chemotherapy-associated liver injuries except for steatosis, suggest study findings published in the Archives of Surgery.

3 Sep 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Pediatric liver transplant recipients have increased risk of death when from obese donors

Children undergoing liver transplantation are at greater risk of graft loss and death from adult organ donors who are severely obese according to research published in the August issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases. The study, funded in part by a grant from the National Institutes of Health (NIH), found that pediatric donor body mass index (BMI) did not increase mortality risk in this pediatric population.

1 Aug 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

Mouse model demonstrates role of AEG-1 in hepatocellular carcinoma

Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step in understanding the molecular mechanisms of liver cancer progression and could lead to novel therapies for the disease.

8 Jul 2012

People with fatty livers need to lose weight

Exercising moderately for 150 to 300 minutes a week does not improve lipoprotein metabolism in obese people with nonalcoholic fatty lipid disease, show findings from a US study.

31 May 2012

Obese patients with fatty liver disease show only small benefit on lipoprotein levels with moderate exercise

New research found that moderate exercise does not improve lipoprotein concentrations in obese patients with non alcoholic fatty liver disease (NAFLD). Results published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, report that moderate physical activity produces only a small decrease in triglyceride and alanine transaminase (ALT) levels.

24 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

EASL publishes new clinical practice guideline on ALD

EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

19 Apr 2012

Gut microbiota plays a causal role in development of diabetes and NAFLD

Exciting new data presented today at the International Liver Congress 2012 shows the gut microbiota's causal role in the development of diabetes and non-alcoholic fatty liver disease (NAFLD), independent of obesity.

19 Apr 2012

Caffeine consumption reduces risk of advanced fibrosis in NAFLD patients

Caffeine consumption has long been associated with decreased risk of liver disease and reduced fibrosis in patients with chronic liver disease. Now, newly published research confirms that coffee caffeine consumption reduces the risk of advanced fibrosis in those with nonalcoholic fatty liver disease (NAFLD).

3 Feb 2012

WSU professors receive NSF grant to develop math model of liver metabolism

Predicting problems in one of the body's most complex organs soon may become easier because of work being done by Wayne State University researchers.

20 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

Scientists identify A2bAR as possible new therapeutic target against atherosclerosis

Researchers from Boston University School of Medicine (BUSM) have identified for the first time the A2b adenosine receptor (A2bAR) as a possible new therapeutic target against atherosclerosis resulting from a diet high in fat and cholesterol.

13 Dec 2011

Mediterranean Diet beneficial even without weight loss

The benefits of the Mediterranean Diet go beyond weight loss, even when weight loss isn't achieved. Researchers from St. Vincent's Hospital, Melbourne, studied 12 patients without diabetes who had nonalcoholic fatty liver disease (NAFLD), and the results of their study demonstrated that liver health was improved even without weight loss.

7 Nov 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011